Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
DiaSorin S.p.A., headquartered in Italy, is a prominent player in the pharmaceutical preparation manufacturing industry, specialising in the development and production of diagnostic solutions. Founded in 1968, the company has established a strong global presence, with significant operations across Europe, North America, and Asia.
DiaSorin is renowned for its innovative immunodiagnostic and molecular diagnostic products, which are designed to enhance patient care through accurate and timely testing. The company’s unique offerings include a wide range of assays for infectious diseases, oncology, and endocrinology, setting it apart in a competitive market.
With a commitment to research and development, DiaSorin has achieved notable milestones, including strategic acquisitions that have expanded its product portfolio and market reach. As a leader in the diagnostics field, DiaSorin continues to drive advancements that improve healthcare outcomes worldwide.
+24 vs industry average
Diasorin’s score of 66 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
DiaSorin, a pharmaceutical preparation manufacturer based in IT, reported total carbon emissions of approximately 113.8 million kg CO2e in 2025. This includes 4,184,000 kg CO2e from Scope 1, 12,807,000 kg CO2e from Scope 2 (market-based), and 96,847,000 kg CO2e from Scope 3 emissions.
For 2024, the company's total carbon emissions were about 152.3 million kg CO2e, comprising 3,513,000 kg CO2e from Scope 1, 12,132,000 kg CO2e from Scope 2 (market-based), and 136,702,000 kg CO2e from Scope 3.
In 2023, DiaSorin's combined Scope 1 and Scope 2 emissions totalled 18,895,000 kg CO2e, with 3,894,000 kg CO2e from Scope 1 and 15,001,000 kg CO2e from Scope 2. Scope 3 data was not available for this year.
DiaSorin is committed to achieving Net Zero emissions by 2050 across all scopes. The company also projects a near-term reduction target for carbon emissions, aiming to decrease them to 305.01 tonnes CO2e by 2028, representing a 18.52% reduction from 2023 levels.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more